QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NYSE:PEN

Penumbra - PEN Stock Forecast, Price & News

$169.72
-4.97 (-2.85%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$167.73
$172.73
50-Day Range
$116.09
$174.69
52-Week Range
$114.86
$293.20
Volume
251,432 shs
Average Volume
302,478 shs
Market Capitalization
$6.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$218.78

Penumbra MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
28.9% Upside
$218.78 Price Target
Short Interest
Healthy
5.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
0.15mentions of Penumbra in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$57,968 Sold Last Quarter
Proj. Earnings Growth
352.00%
From $0.25 to $1.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

181st out of 1,124 stocks

Surgical & Medical Instruments Industry

14th out of 113 stocks

PEN stock logo

About Penumbra (NYSE:PEN) Stock

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra Price Performance

Shares of NYSE:PEN traded down $4.97 during midday trading on Tuesday, reaching $169.72. The company's stock had a trading volume of 251,432 shares, compared to its average volume of 302,478. The business's fifty day simple moving average is $135.13 and its 200-day simple moving average is $172.22. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.93 and a quick ratio of 2.90. Penumbra has a fifty-two week low of $114.86 and a fifty-two week high of $293.20. The company has a market capitalization of $6.43 billion, a P/E ratio of -326.38 and a beta of 0.73.

Penumbra (NYSE:PEN - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.07. The company had revenue of $208.30 million for the quarter, compared to the consensus estimate of $206.24 million. Penumbra had a positive return on equity of 0.97% and a negative net margin of 2.40%. The firm's quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.21 EPS. As a group, equities research analysts expect that Penumbra will post 0.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PEN shares. Deutsche Bank Aktiengesellschaft lowered their target price on Penumbra from $250.00 to $163.00 in a report on Thursday, July 21st. William Blair reissued an "outperform" rating on shares of Penumbra in a research report on Tuesday, May 3rd. Royal Bank of Canada initiated coverage on shares of Penumbra in a research report on Monday, July 18th. They issued an "outperform" rating and a $195.00 price target for the company. Wells Fargo & Company lowered their price objective on shares of Penumbra from $321.00 to $265.00 in a research report on Wednesday, May 4th. Finally, Truist Financial reduced their target price on Penumbra to $180.00 in a report on Friday, July 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Penumbra has a consensus rating of "Moderate Buy" and an average price target of $218.78.

Insider Buying and Selling

In related news, Director Thomas Wilder sold 248 shares of the stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $123.64, for a total transaction of $30,662.72. Following the completion of the transaction, the director now owns 462 shares in the company, valued at $57,121.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 451 shares of company stock valued at $57,968. Company insiders own 5.50% of the company's stock.

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

Penumbra (NYSE:PEN) Trading Up 10.5% After Strong Earnings
Penumbra (NYSE:PEN) Shares Up 10.5% on Strong Earnings
Penumbra (PEN) to Release Earnings on Thursday
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Company Calendar

Last Earnings
8/04/2022
Today
8/16/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
3,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$218.78
High Stock Price Forecast
$300.00
Low Stock Price Forecast
$163.00
Forecasted Upside/Downside
+28.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$5.28 million
Pretax Margin
-4.89%

Debt

Sales & Book Value

Annual Sales
$747.59 million
Cash Flow
$1.13 per share
Book Value
$25.53 per share

Miscellaneous

Free Float
35,804,000
Market Cap
$6.43 billion
Optionable
Optionable
Beta
0.73

Key Executives














PEN Stock - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PEN shares.
View PEN analyst ratings
or view top-rated stocks.

What is Penumbra's stock price forecast for 2022?

9 analysts have issued 1-year target prices for Penumbra's shares. Their PEN share price forecasts range from $163.00 to $300.00. On average, they anticipate the company's share price to reach $218.78 in the next year. This suggests a possible upside of 28.9% from the stock's current price.
View analysts price targets for PEN
or view top-rated stocks among Wall Street analysts.

How have PEN shares performed in 2022?

Penumbra's stock was trading at $287.32 at the start of the year. Since then, PEN shares have decreased by 40.9% and is now trading at $169.72.
View the best growth stocks for 2022 here
.

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our PEN earnings forecast
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) issued its quarterly earnings data on Thursday, August, 4th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.07. The company earned $208.30 million during the quarter, compared to analyst estimates of $206.24 million. Penumbra had a positive trailing twelve-month return on equity of 0.97% and a negative net margin of 2.40%. The business's quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.21 EPS.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra issued an update on its FY 2022 earnings guidance on Thursday, August, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $860.00 million-$875.00 million, compared to the consensus revenue estimate of $869.01 million.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.92%), Baillie Gifford & Co. (3.38%), Price T Rowe Associates Inc. MD (3.25%), Clearbridge Investments LLC (2.69%), William Blair Investment Management LLC (2.58%) and State Street Corp (2.56%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Don W Kassing, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends
.

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $169.72.

How much money does Penumbra make?

Penumbra (NYSE:PEN) has a market capitalization of $6.43 billion and generates $747.59 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Penumbra have?

The company employs 3,800 workers across the globe.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.

This page (NYSE:PEN) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.